Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease
Open accessThe DOI matches its Crossref record; 42 of the 43 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Recent studies indicate an increased frequency of mutations in the gene encoding glucocerebrosidase (GBA), a deficiency of which causes Gaucher's disease, among patients with Parkinson's disease. We aimed to ascertain the frequency of GBA mutations in an ethnically diverse group of patients with Parkinson's disease. METHODS: Sixteen centers participated in our international, collaborative study: five from the Americas, six from Europe, two from Israel, and three from Asia. Each center genotyped a standard DNA panel to permit comparison of the genotyping results across centers. Genotypes and phenotypic data from a total of 5691 patients with Parkinson's disease (780 Ashkenazi Jews) and 4898 controls (387 Ashkenazi Jews) were analyzed, with multivariate logistic-regression models and the Mantel-Haenszel procedure used to estimate odds ratios across centers. RESULTS: All 16 centers could detect two GBA mutations, L444P and N370S. Among Ashkenazi Jewish subjects, either mutation was found in 15% of patients and 3% of controls, and among non-Ashkenazi Jewish subjects, either mutation was found in 3% of patients and less than 1% of controls. GBA was fully sequenced for 1883 non-Ashkenazi Jewish patients, and mutations were identified in 7%, showing that limited mutation screening can miss half the mutant alleles. The odds ratio for any GBA mutation in patients versus controls was 5.43 across centers. As compared with patients who did not carry a GBA mutation, those with a GBA mutation presented earlier with the disease, were more likely to have affected relatives, and were more likely to have atypical clinical manifestations. CONCLUSIONS: Data collected from 16 centers demonstrate that there is a strong association between GBA mutations and Parkinson's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“A compartment located at the trans Golgi where autolysosomes and MTOR accumulate during RAS-induced senescence”
From Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). (2016) · cites this paper as [1769]
Experimental — accuracy not yet measuredIn the citing paper
“there is an increased frequency of mutations in the gene encoding GBA among patients with Parkinson’s disease (e.g. Aharon-Peretz et al. 2004; Clark et al. 2007; Gan-Or et al. 2008; Lwin et al. 2004), and vice versa (Sidransky et al. 2009).”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Metabolic and Molecular Bases of Inherited Disease
Scriver, R. C. (1995) · Medical Entomology and Zoology · Cited by 12,101
The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease.
Gibb, W. R., & Lees, A. J. (1988) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.51.6.745 · Cited by 3,481
ON ESTIMATING THE RELATION BETWEEN BLOOD GROUP AND DISEASE
WOOLF, B. (1955) · Annals of Human Genetics · doi:10.1111/j.1469-1809.1955.tb01348.x · Cited by 2,723
Glucocerebrosidase mutations in clinical and pathologically proven Parkinson’s disease
Neumann, J., Bras, J., Deas, E., O'Sullivan, S. S., Parkkinen, L., Lachmann, R. H., Li, A., Holton, J., Guerreiro, R., Paudel, R., et al. (2009) · Brain · doi:10.1093/brain/awp044 · Cited by 696 · cited 1×
“R496H (7 recombinant alleles) (10) c.84dupG ( 17 )”
Self-citationGaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA)
Hruska, K. S., LaMarca, M. E., Scott, C. R., & Sidransky, E. (2008) · Human Mutation · doi:10.1002/humu.20676 · Cited by 678
Self-citationMutations in the Glucocerebrosidase Gene and Parkinson's Disease in Ashkenazi Jews
Aharon-Peretz, J., Rosenbaum, H., & Gershoni-Baruch, R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033277 · Cited by 597
Self-citationOccurrence of Parkinson's syndrome in type 1 Gaucher disease
Neudorfer, O., Giladi, N., Elstein, D., Abrahamov, A., Turezkite, T., Aghai, E., Reches, A., Bembi, B., & Zimran, A. (1996) · QJM · doi:10.1093/qjmed/89.9.691 · Cited by 401
Self-citationGaucher disease: complexity in a “simple” disorder
Sidransky, E. (2004) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2004.08.015 · Cited by 399 · cited 7×
“Patients 311 (0) 186:123 (2) NP 7 (2) Controls 473 (0) 267:206 64.1 8 ( 2 )”
InfluentialSelf-citationGlucocerebrosidase mutations in subjects with parkinsonism
Lwin, A. (2004) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2003.11.004 · Cited by 371
Parkinsonism among Gaucher disease carriers
Goker-Alpan, O., Schiffmann, R., LaMarca, M. E., Nussbaum, R. L., McInerney-Leo, A., & Sidransky, E. (2004) · Journal of Medical Genetics · doi:10.1136/jmg.2004.024455 · Cited by 366
Self-citation
Research works printed but not linked: 1
- 10.1002/(sici)1096-8652(199907)61:3<216::aid-ajh12>3.0.co;2-b · doi:10.1002/(sici)1096-8652(199907)61:3<216::aid-ajh12>3.0.co;2-b
Cited by
Items 501–600 of 1,008
Kurzawa-Akanbi, M., Tammireddy, S., Fabrik, I., Gliaudelytė, L., Doherty, M. K., Heap, R., Matečko-Burmann, I., Burmann, B. M., Trost, M., Lucocq, J. M., et al. (2021) · Acta Neuropathologica · doi:10.1007/s00401-021-02367-3 · Cited by 69
New therapeutic approaches to Parkinson's disease targeting GBA, LRRK2 and Parkin
Senkevich, K. A., Rudakou, U., & Gan‐Or, Z. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108822 · Cited by 75
Self-citationGlucocerebrosidase Mutations alter the endoplasmic reticulum and lysosomes in Lewy body disease
Kurzawa‐Akanbi, M., Hanson, P. S., Blain, P. G., Lett, D. J., McKeith, I. G., Chinnery, P. F., & Morris, C. M. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2012.07879.x · Cited by 69
Aggregation of α-synuclein in brain samples from subjects with glucocerebrosidase mutations
Choi, J. H., Stubblefield, B., Cookson, M. R., Goldin, E., Velayati, A., Tayebi, N., & Sidransky, E. (2011) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2011.06.008 · Cited by 70
Self-citationSmall Molecule Chaperones for the Treatment of Gaucher Disease and GBA1-Associated Parkinson Disease
Han, T., Sam, R., & Sidransky, E. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00271 · Cited by 74
Self-citationMitochondrial Function and Parkinson’s Disease: From the Perspective of the Electron Transport Chain
Li, J., Lin, T.-Y., Chen, P., Guo, T.-N., Huang, S., Chen, C., Lin, C., & Chan, C. (2021) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2021.797833 · Cited by 78
Self-citationCrosiers, D., Theuns, J., Cras, P. P., & Broeckhoven, C. V. (2011) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2011.07.003 · Cited by 87
“…factors, such as the H1 haplotype of the microtubule-associated protein tau (MAPT) gene (WilliamsGray et al., 2009; Seto-Salvia et al., 2011) and heterozygous mutations in beta-glucosidase (GBA) may modulate the dementia risk in monogenic PD patients (Sidransky et al., 2009; Neumann et al., 2009).”
BackgroundTargeting heat shock proteins to modulate α-synuclein toxicity
Jones, D. R., Moussaud, S., & McLean, P. J. (2013) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285613493469 · Cited by 80
Are Major Dementias Triggered by Poor Blood Flow to the Brain? Theoretical Considerations
de la Torre, J. C. (2017) · Journal of Alzheimer's Disease · doi:10.3233/jad-161266 · Cited by 69
Cellular models as tools for the study of the role of alpha-synuclein in Parkinson's disease
Lázaro, D. F., Pavlou, M. A. S., & Outeiro, T. F. (2017) · Experimental Neurology · doi:10.1016/j.expneurol.2017.05.007 · Cited by 76
Brahmachari, S., Lee, S., Kim, S., Yuan, C., Karuppagounder, S. S., Ge, P., Shi, R., Kim, E. J., Liu, A., Kim, D., et al. (2019) · Brain · doi:10.1093/brain/awz172 · Cited by 73
“In addition there are a number of mutations or polymorphisms in other genes that are either causal or increase the risk of developing Parkinson’s disease (Ramirez et al., 2006; Satake et al., 2009; Sidransky et al., 2009; Simon-Sanchez et al., 2009; Shulman et al., 2011; Vilarino-Guell et al., 2011; Zimprich et al., 2…”
BackgroundGuidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)
Klionsky, D. J., Abdelmohsen, K., Abe, A., Abedin, J., Abeliovich, H., Acevedo‐Arozena, A., Adachi, H., Adams, C. M., Adams, P. D., Adeli, K., et al. (2016) · Parasites & Vectors · doi:10.5167/uzh-131237 · Cited by 169
Parkinson’s Disease-Related Genes and Lipid Alteration
Fais, M., Dore, A., Galioto, M., Galleri, G., Crosio, C., & Iaccarino, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147630 · Cited by 72
Respiratory disorders of Parkinson’s disease
Aquino, Y. C., Cabral, L. M., Miranda, N. C., Naccarato, M. C., Falquetto, B., Moreira, T. S., & Takakura, A. C. T. (2021) · Journal of Neurophysiology · doi:10.1152/jn.00363.2021 · Cited by 74
Menozzi, E., Toffoli, M., & Schapira, A. H. V. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108419 · Cited by 74
What can biomarkers tell us about cognition in Parkinson's disease?
Mollenhauer, B., Rochester, L., Chen‐Plotkin, A. S., & Brooks, D. J. (2014) · Movement Disorders · doi:10.1002/mds.25846 · Cited by 80
Disease variants in genomes of 44 centenarians
Freudenberg‐Hua, Y., Freudenberg, J., Vacic, V., Abhyankar, A., Emde, A., Ben‐Avraham, D., Barzilai, N., Oschwald, D., Christen, E., Koppel, J., et al. (2014) · Molecular Genetics & Genomic Medicine · doi:10.1002/mgg3.86 · Cited by 67
Pathological role of lipid interaction with α-synuclein in Parkinson's disease
Suzuki, M., Sango, K., Wada, K., & Nagai, Y. (2018) · Neurochemistry International · doi:10.1016/j.neuint.2017.12.014 · Cited by 68
Arylsulfatase A, a genetic modifier of Parkinson’s disease, is an α-synuclein chaperone
Lee, J. S., Kanai, K., Suzuki, M., Kim, W. S., Yoo, H. S., Fu, Y., Kim, D.-K., Jung, B. C., Choi, M.-S., Oh, K. W., et al. (2019) · Brain · doi:10.1093/brain/awz205 · Cited by 69
Clark, L. N., Chan, R., Cheng, R., Liu, X., Park, N., Parmalee, N., Kisselev, S., Cortes, E., Torres, P. A., Pastores, G. M., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0125204 · Cited by 67
Self-citationClinical prodromes of neurodegeneration in Anderson-Fabry disease
Löhle, M., Hughes, D. A., Milligan, A., Richfield, L., Reichmann, H., Mehta, A. B., & Schapira, A. H. V. (2015) · Neurology · doi:10.1212/wnl.0000000000001450 · Cited by 73
Induction of the type I interferon response in neurological forms of Gaucher disease
Vitner, E. B., Farfel-Becker, T., Ferreira, N. S., Leshkowitz, D., Sharma, P., Lang, K. S., & Futerman, A. H. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0570-2 · Cited by 67
A Large‐Scale Full GBA1 Gene Screening in Parkinson's Disease in the Netherlands
den Heijer, J. M., Cullen, V., Quadri, M., Schmitz, A., Hilt, D. C., Lansbury, P. T., Berendse, H. W., van de Berg, W. D. J., de Bie, R. M. A., Boertien, J. M., et al. (2020) · Movement Disorders · doi:10.1002/mds.28112 · Cited by 74
“References: Ashkenazi Jewish (1), Netherlands (current study), France (2), Colombia (3), Norway (4), Spain (5), United States (6), United Kingdom (7), eastern Canada (8), Belgium (9), Japan (10), New Zealand (11), Sweden (12), Peru (3), Russia (13), Greece (14), Portugal (15), Korea (16), and north Africa (17).”
BackgroundCognitive Impairment in Older Adults and Therapeutic Strategies
Montine, T. J., Bukhari, S. A., & White, L. R. (2020) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000031 · Cited by 71
“The most common genetic risk for PD is heterozygosity for mutations in GBA, which encodes glucocerebrosidase (Mata et al., 2008; Sidransky et al., 2009).”
BackgroundDysregulation of protein phosphatase 2A in parkinson disease and dementia with lewy bodies
Park, H., Lee, K., Park, E. S., Oh, S., Yan, R., Zhang, J., Beach, T. G., Adler, C. H., Voronkov, M., Braithwaite, S. P., et al. (2016) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.337 · Cited by 66
Mutated ATP10B increases Parkinson’s disease risk by compromising lysosomal glucosylceramide export
Martin, S., Smolders, S., den Haute, C. V., Heeman, B., van Veen, S., Crosiers, D., Beletchi, I., Verstraeten, A., Gossye, H., Gelders, G., et al. (2020) · Acta Neuropathologica · doi:10.1007/s00401-020-02145-7 · Cited by 70
Astrocytes and microglia in neurodegenerative diseases: Lessons from human in vitro models
Franklin, H., Clarke, B. E., & Patani, R. (2021) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2020.101973 · Cited by 66
“Gaucher disease (GD) is a lysosomal storage disorder elicited by mutations in the gene that encodes the Glucocerebrosidase beta 1 (GBA1) enzyme, also representing a critical risk factor for PD and the related dementia with Lewy bodies (Sidransky et al., 2009; Nalls et al., 2013).”
Clinical, mechanistic, biomarker, and therapeutic advances in GBA1-associated Parkinson’s disease
Zhang, X., Wu, H., Tang, B., & Guo, J. (2024) · Translational Neurodegeneration · doi:10.1186/s40035-024-00437-6 · Cited by 71
Bayati, A., Ayoubi, R., Aguila, A., Zorca, C. E., Deyab, G., Han, C., Recinto, S. J., Nguyen, E., Rocha, C., Maussion, G., et al. (2024) · Nature Neuroscience · doi:10.1038/s41593-024-01775-4 · Cited by 72
Self-citationGlucocerebrosidase in the pathogenesis and treatment of Parkinson disease
Schapira, A. H. V., & Gegg, M. E. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1300822110 · Cited by 69
Glucocerebrosidase mutations in primary parkinsonism
Asselta, R., Rimoldi, V., Siri, C., Cilia, R., Guella, I., Tesei, S., Soldà, G., Pezzoli, G., Duga, S., & Goldwurm, S. (2014) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2014.09.003 · Cited by 72
Xie, W., Wan, O. W., & Chung, K. K. K. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2010.07.014 · Cited by 76
Next-generation sequencing reveals substantial genetic contribution to dementia with Lewy bodies
Geiger, J. T., Ding, J., Crain, B., Pletnikova, O., Letson, C., Dawson, T. M., Rosenthal, L. S., Pantelyat, A., Gibbs, J. R., Albert, M. S., et al. (2016) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.06.004 · Cited by 66
Self-citationKuo, C. J., Kallemeijn, W. W., Lelieveld, L. T., Mirzaian, M., Zoutendijk, I., Vardi, A., Futerman, A. H., Meijer, A. H., Spaink, H. P., Overkleeft, H. S., et al. (2019) · FEBS Journal · doi:10.1111/febs.14744 · Cited by 66
Horowitz, M., Braunstein, H., Zimran, A., Revel‐Vilk, S., & Göker-Alpan, Ö. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114402 · Cited by 73
Unraveling Parkinson’s Disease Neurodegeneration: Does Aging Hold the Clues?
Coleman, C., & Martin, I. (2022) · Journal of Parkinson s Disease · doi:10.3233/jpd-223363 · Cited by 77
Prasanth, M. I., Sivamaruthi, B. S., Cheong, C. S. Y., Verma, K., Tencomnao, T., Brimson, J. M., & Prasansuklab, A. (2024) · Antioxidants · doi:10.3390/antiox13050606 · Cited by 71
“Mutations in GBA , the gene coding for lysosomal hydrolase enzyme glucocerebrosidase (GCase), have been identified to be related to PD [146].”
BackgroundGBA Analysis in Next-Generation Era
Zampieri, S., Cattarossi, S., Bembi, B., & Dardis, A. (2017) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2017.05.005 · Cited by 73
Michelakakis, H., Xiromerisiou, G., Dardiotis, E., Bozi, M., Vassilatis, D., Kountra, P., Patramani, G., Moraitou, M., Papadimitriou, D., Stamboulis, E., et al. (2012) · Movement Disorders · doi:10.1002/mds.24886 · Cited by 64
Leonard, H. L., Blauwendraat, C., Krohn, L., Faghri, F., Iwaki, H., Ferguson, G. D., Day-Williams, A., Stone, D. J., Singleton, A., Nalls, M. A., et al. (2019) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2019-106283 · Cited by 69
Self-citationNiemann-Pick C Disease Gene Mutations and Age-Related Neurodegenerative Disorders
Zech, M., Nübling, G., Castrop, F., Jochim, A., Schulte, E. C., Mollenhauer, B., Lichtner, P., Peters, A., Gieger, C., Marquardt, T., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0082879 · Cited by 60
The Genetic Basis of Cognitive Impairment and Dementia in Parkinson’s Disease
Collins, L. M., & Williams-Gray, C. H. (2016) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2016.00089 · Cited by 62
Neuropsychiatric characteristics of GBA-associated Parkinson disease
Swan, M. C., Doan, N., Ortega, R., Barrett, M. J., Nichols, W. C., Ozelius, L. J., Soto‐Valencia, J., Boschung, S., Deik, A., Sarva, H., et al. (2016) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2016.08.059 · Cited by 66
Self-citationGBA -Associated Parkinson’s Disease: Progression in a Deep Brain Stimulation Cohort
Lythe, V., Athauda, D. S., Foley, J. A., Mencacci, N. E., Jahanshahi, M., Cipolotti, L., Hyam, J. A., Zrinzo, L. U., Hariz, M. I., Hardy, J., et al. (2017) · Journal of Parkinson s Disease · doi:10.3233/jpd-171172 · Cited by 67
STING signaling in the brain: Molecular threats, signaling activities, and therapeutic challenges
Yang, K., Tang, Z., Xing, C., & Yan, N. (2023) · Neuron · doi:10.1016/j.neuron.2023.10.014 · Cited by 69
Polygenic determinants of Parkinson's disease in a Chinese population
Guo, J., Li, K., Yu, R.-L., Sun, Q.-Y., Wang, L., Yao, L., Hu, Y., Lv, Z., Luo, L.-Z., Shen, L. H., et al. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.12.030 · Cited by 63
“Because PARK16 and L444P in GBA gene were reported associating with the risk of Asian PD (Satake et al., 2009; Sidransky et al., 2009; Sun et al., 2010), we also analyzed the 2 loci in this study.”
ResultCeramides in Parkinson’s Disease: From Recent Evidence to New Hypotheses
Plotegher, N., Bubacco, L., Greggio, E., & Civiero, L. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00330 · Cited by 71
The SPID-GBA study: Sex distribution, Penetrance, Incidence, and Dementia in GBA-PD
Straniero, L., Asselta, R., Bonvegna, S., Rimoldi, V., Melistaccio, G., Soldà, G., Aureli, M., Porta, M. G. D., Lucca, U., Fonzo, A. D., et al. (2020) · Neurology Genetics · doi:10.1212/nxg.0000000000000523 · Cited by 65
“Among predisposing genes, GBA (encoding the lysosomal beta-glucocerebrosidase) represents the most common large-effect genetic factor associated with PD in all analyzed populations.(5,6) Patients with heterozygous GBA mutations have peculiar characteristics, including earlier onset, more rapid progression of motor imp…”
BackgroundLysoplex: An efficient toolkit to detect DNA sequence variations in the autophagy-lysosomal pathway
Di Fruscio, G., Schulz, A., De Cegli, R., Savarese, M., Mutarelli, M., Parenti, G., Banfi, S., Braulke, T., Nigro, V., & Ballabio, A. (2015) · Autophagy · doi:10.1080/15548627.2015.1043077 · Cited by 62
A spectrum of recessiveness among Mendelian disease variants in UK Biobank
Barton, A. R., Hujoel, M. L. A., Mukamel, R. E., Sherman, M. A., & Loh, P. (2022) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2022.05.008 · Cited by 64
Glucocerebrosidase mutations and Parkinson disease
Vieira, S. R. L., & Schapira, A. H. V. (2022) · Journal of Neural Transmission · doi:10.1007/s00702-022-02531-3 · Cited by 71
Glucosylsphingosine (Lyso-Gb1) as a reliable biomarker in Gaucher disease: a narrative review
Giuffrida, G., Markovic, U., Condorelli, A., Calafiore, V., Nicolosi, D., Calagna, M., Grasso, S., Ragusa, M. T. V., Gentile, J., & Napolitano, M. (2023) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-023-02623-7 · Cited by 62
Flores‐León, M., & Outeiro, T. F. (2023) · Acta Neuropathologica · doi:10.1007/s00401-023-02601-0 · Cited by 70
He, Y., Kaya, I., Shariatgorji, M., Lundkvist, J., Wahlberg, L. U., Nilsson, A., Mamula, D., Kehr, J., Zarȩba-Pasławska, J., Biverstål, H., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41539-5 · Cited by 66
Genetic risk factors for cognitive decline in Parkinson's disease: a review of the literature
Fagan, E., & Pihlstrøm, L. (2017) · European Journal of Neurology · doi:10.1111/ene.13258 · Cited by 70
Linking mitochondrial dysfunction to neurodegeneration in lysosomal storage diseases
Saffari, A., Kölker, S., Hoffmann, G. F., & Ebrahimi‐Fakhari, D. (2017) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-017-0048-0 · Cited by 66
Increased yield of full GBA sequencing in Ashkenazi Jews with Parkinson's disease
Ruskey, J. A., Greenbaum, L., Roncière, L., Alam, A., Spiegelman, D., Liong, C., Levy, O. A., Waters, C., Fahn, S., Marder, K. S., et al. (2018) · European Journal of Medical Genetics · doi:10.1016/j.ejmg.2018.05.005 · Cited by 66
“[1, 5] This may suggest that in order to develop GD in carriers of these variants, other genetic or environmental modifiers are required.”
BackgroundSelf-citationIkuno, M., Yamakado, H., Akiyama, H., Parajuli, L. K., Taguchi, K., Hara, J., Uemura, N., Hatanaka, Y., Higaki, K., Ohno, K., et al. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddz030 · Cited by 68
Glucocerebrosidase deficiency promotes release of α-synuclein fibrils from cultured neurons
Gegg, M. E., Verona, G., & Schapira, A. H. V. (2020) · Human Molecular Genetics · doi:10.1093/hmg/ddaa085 · Cited by 66
“Mutations in the GBA gene are numerically the most important genetic risk factor for Parkinson disease (PD) identified to date, accounting for 5-25% of all PD cases depending on population and age (1,2).”
Parkinsonism and Related Disorders
Slow, E. J., & Lang, A. E. (2019) · DeckerMed Transitional Year Weekly Curriculum™ · doi:10.2310/tywc.1178 · Cited by 62
Self-citationParkinson's disease – genetic cause
Cherian, A., Divya, K. P., & Vijayaraghavan, A. (2023) · Current Opinion in Neurology · doi:10.1097/wco.0000000000001167 · Cited by 70
Lipids as Emerging Biomarkers in Neurodegenerative Diseases
Wei, J. C., Wong, L. C., & Boland, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms25010131 · Cited by 65
“GBA1 - associated PD ( GBA -PD) is similar to idiopathic PD, however, subjects with GBA1 mutations display an earlier onset and higher prevalence of cognitive changes [63,64].”
BackgroundPaediatric stroke: genetic insights into disease mechanisms and treatment targets
Munot, P., Crow, Y. J., & Ganesan, V. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70327-6 · Cited by 61
Advances in GBA-associated Parkinson's disease – Pathology, presentation and therapies
Barkhuizen, M., Anderson, D. G., & Grobler, A. (2015) · Neurochemistry International · doi:10.1016/j.neuint.2015.12.004 · Cited by 68
Glucocerebrosidase modulates cognitive and motor activities in murine models of Parkinson’s disease
Rockenstein, E. M., Clarke, J. L., Viel, C., Panarello, N. M., Treleaven, C. M., Kim, C., Spencer, B. J., Adame, A., Park, H. J., Dodge, J. C., et al. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw124 · Cited by 70
Lysosomal trafficking defects link Parkinson's disease with Gaucher's disease
Wong, Y. C., & Krainc, D. (2016) · Movement Disorders · doi:10.1002/mds.26802 · Cited by 59
Mutation analysis of Parkinson's disease genes in a Russian data set
Emelyanov, A., Usenko, T. S., Tesson, C., Senkevich, K. A., Nikolaev, M. A., Miliukhina, I. V., Kopytova, A. E., Timofeeva, A., Yakimovsky, A. F., Lesage, S., et al. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.06.027 · Cited by 61
Self-citationNicotinic Acetylcholine Receptor Signaling in Neuroprotection
Akaike, A., Shimohama, S., & Misu, Y. (2018) · Springer eBooks · doi:10.1007/978-981-10-8488-1 · Cited by 67
The Future of Targeted Gene-Based Treatment Strategies and Biomarkers in Parkinson’s Disease
Polissidis, A., Petropoulou-Vathi, L., Nakos‐Bimpos, M., & Rideout, H. J. (2020) · Biomolecules · doi:10.3390/biom10060912 · Cited by 64
A comprehensive analysis of SNCA ‐related genetic risk in sporadic parkinson disease
Pihlstrøm, L., Blauwendraat, C., Cappelletti, C., Berge‐Seidl, V., Langmyhr, M., Henriksen, S. P., van de Berg, W. D. J., Gibbs, J. R., Cookson, M. R., Singleton, A., et al. (2018) · Annals of Neurology · doi:10.1002/ana.25274 · Cited by 66
“This combination would be exceedingly rare in the population but carries an estimated PD risk of approximately 4-fold, comparable to the effect of protein-coding high-risk variants in GBA.(29)”
BackgroundSelf-citationToffoli, M., Chen, X., Sedlazeck, F. J., Lee, C.-Y., Mullin, S., Higgins, A., Koletsi, S., Garcia-Segura, M. E., Sammler, E., Scholz, S. W., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-03610-7 · Cited by 59
Gaucher disease: Basic and translational science needs for more complete therapy and management
Grabowski, G. A., Antommaria, A. H. M., Kolodny, E. H., & Mistry, P. K. (2020) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2020.12.291 · Cited by 64
Complement cascade functions during brain development and neurodegeneration
Fatoba, O., Itokazu, T., & Yamashita, T. (2021) · FEBS Journal · doi:10.1111/febs.15772 · Cited by 61
Role of AMBRA1 in mitophagy regulation: emerging evidence in aging-related diseases
Rienzo, M. D., Romagnoli, A., Refolo, G., Vescovo, T., Ciccosanti, F., Zuchegna, C., Lozzi, F., Occhigrossi, L., Piacentini, M., & Fimia, G. M. (2024) · Autophagy · doi:10.1080/15548627.2024.2389474 · Cited by 63
Lysosomal function in macromolecular homeostasis and bioenergetics in Parkinson's disease
Schneider, L., & Zhang, J. (2010) · Molecular Neurodegeneration · doi:10.1186/1750-1326-5-14 · Cited by 58
Jung, O., Patnaik, S., Marugán, J., Sidransky, E., & Westbroek, W. (2016) · Expert Review of Proteomics · doi:10.1080/14789450.2016.1174583 · Cited by 63
Self-citationThe lysosomal storage disease continuum with ageing-related neurodegenerative disease
Lloyd‐Evans, E., & Haslett, L. J. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2016.07.005 · Cited by 62
Centrality of Early Synaptopathy in Parkinson’s Disease
Imbriani, P., Schirinzi, T., Meringolo, M., Mercuri, N. B., & Pisani, A. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00103 · Cited by 60
Rare Variants in Specific Lysosomal Genes Are Associated With Parkinson's Disease
Hopfner, F., Mueller, S. H., Szymczak, S., Junge, O., Tittmann, L., May, S., Lohmann, K., Grallert, H., Lieb, W., Strauch, K., et al. (2020) · Movement Disorders · doi:10.1002/mds.28037 · Cited by 60
“The association between rare variants in GBA and PD is well known.(15) Of 5 genes, 4 identified in this study are well-”
BackgroundSelf-citationLi, D., Mastaglia, F. L., Fletcher, S., & Wilton, S. D. (2020) · Medicinal Research Reviews · doi:10.1002/med.21718 · Cited by 61
“However, the prevalence of GBA mutations varies in different populations, with the highest prevalence being in Ashkenazi Jewish PD patients (20%).(53) While, it is clear that GBA mutations cause autophagy–lysosomal dysfunction, the specific mechanisms involved remain unclear.”
BackgroundGaucher disease – more than just a rare lipid storage disease
Roh, J., Subramanian, S., Weinreb, N. J., & Kartha, R. V. (2022) · Journal of Molecular Medicine · doi:10.1007/s00109-021-02174-z · Cited by 60
Gaucher disease provides a unique window into Parkinson disease pathogenesis
Hertz, E., Chen, Y., & Sidransky, E. (2024) · Nature Reviews Neurology · doi:10.1038/s41582-024-00999-z · Cited by 68
Self-citationThe contribution of Niemann-Pick SMPD1 mutations to Parkinson disease in Ashkenazi Jews
Dagan, E., Schlesinger, I., Ayoub, M., Mory, A., Nassar, M., Kurolap, A., Peretz-Aharon, J., & Gershoni‐Baruch, R. (2015) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2015.06.016 · Cited by 64
Self-citationLiu, G., Chen, M., Mi, N., Yang, W., Li, X., Wang, P., Yin, N., Li, Y., Yue, F., Chan, P., et al. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.06.004 · Cited by 60
The emerging role of autophagic-lysosomal dysfunction in Gaucher disease and Parkinson's disease
Kinghorn, K. J., Asghari, A., & Castillo-Quan, J. I. (2017) · Neural Regeneration Research · doi:10.4103/1673-5374.202934 · Cited by 61
The role of epigenetics in lysosomal storage disorders: Uncharted territory
Hassan, S., Sidransky, E., & Tayebi, N. (2017) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2017.07.012 · Cited by 61
Self-citationLRRK2 and GBA Variants Exert Distinct Influences on Parkinson’s Disease-Specific Metabolic Networks
Schindlbeck, K. A., Vo, A., Nguyen, N., Tang, C. C., Niethammer, M., DHAWAN, V. M., Brandt, V. L., Saunders-Pullman, R. J., Bressman, S., & Eidelberg, D. (2019) · Cerebral Cortex · doi:10.1093/cercor/bhz280 · Cited by 61
Sun, Y., Florer, J. B., Mayhew, C. N., Jia, Z., Zhao, Z., Xu, K., Ran, H., Liou, B., Zhang, W., Setchell, K. D. R., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0118771 · Cited by 59
Gaucher disease paradigm: From ERAD to comorbidity
Bendikov-Bar, I., & Horowitz, M. (2012) · Human Mutation · doi:10.1002/humu.22124 · Cited by 63
“Thus, GD patients and carriers of GD mutations have higher propensity than expected to develop PD [Sidransky et al., 2009; Tayebi et al., 2001], indicating that not only GD pathology but also the presence of one mutant GBA allele increases the risk for the development of PD and is sufficient to…”
BackgroundBiomarkers in Parkinson’s Disease
Morgan, J. C., Mehta, S. H., & Sethi, K. D. (2010) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-010-0144-0 · Cited by 68
“43), indicating that mutations in this gene are strongly associated with development of PD [29].”
BackgroundTowards Unveiling the Genetics of Neurodegenerative Diseases
Lill, C., & Bertram, L. (2011) · Seminars in Neurology · doi:10.1055/s-0031-1299791 · Cited by 57
“Relatives of Gaucher’s patients show an increased incidence of PD. Subsequent association studies on the role of GBA in PD found several relatively rare polymorphisms (L444P, N370S) that very significantly increase the risk for PD.27 These polymorphisms are not included on the current GWAS arrays and were thus—unless…”
BackgroundParkinson’s disease: From human genetics to clinical trials
van der Brug, M. P., Singleton, A., Gasser, T., & Lewis, P. A. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa8280 · Cited by 63
Self-citationGBA1-associated parkinsonism: new insights and therapeutic opportunities
Ryan, E., Seehra, G., Sharma, P., & Sidransky, E. (2019) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000715 · Cited by 61
Self-citationScharenberg, S. G., Poletto, É., Lucot, K. L., Colella, P., Sheikali, A., Montine, T. J., Porteus, M. H., & Gomez‐Ospina, N. (2020) · Nature Communications · doi:10.1038/s41467-020-17148-x · Cited by 59
Ceramide signalling in inherited and multifactorial brain metabolic diseases
Pant, D. C., Aguilera, S., & Pujol, A. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105014 · Cited by 60
“GBA variants may exert this effect by several mechanisms: a lysosomal overload of non-hydrolysed GlcCer, a derangement of vesicle traffic and autophagy/mitophagy, and alterations in cell homeostasis due to ER stress by misfolded proteins (Indellicato & Trinchera, 2019; Robak et al., 2017; Sidransky et al., 2009).”
BackgroundWang, L., Lin, G., Zuo, Z., Li, Y., Byeon, S. K., Pandey, A., & Bellen, H. J. (2022) · Science Advances · doi:10.1126/sciadv.abn3326 · Cited by 60
Boddupalli, C. S., Nair, S., Belinsky, G. S., Gans, J., Teeple, E. A., Nguyen, T., Mehta, S. S., Guo, L., Kramer, M. L., Ruan, J., et al. (2022) · eLife · doi:10.7554/elife.79830 · Cited by 57
“Moreover, heterozygous carriers of GBA mutations are at an increased risk of PD/LBD (Aharon- Peretz et al., 2004; Sidransky and Lopez, 2012; Sidransky et al., 2009).”
BackgroundInfluentialThe Involvement of Neuroinflammation in the Onset and Progression of Parkinson’s Disease
Jurcău, A., Andronie-Cioară, F. L., Nistor-Cseppento, C. D., Pașcalău, N., Rus, M., Vasca, E., & Jurcău, M. C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914582 · Cited by 63
“Homozygous GBA mutations lead to Gaucher’s disease, while heterozygous mutations are recognized as risk factors for PD [193], increasing the risk for developing PD by 1.4-to 10-fold and decreasing the age of onset [194].”
InfluentialLysosome-Mitochondrial Crosstalk in Cellular Stress and Disease
Kiraly, S., Stanley, J., & Eden, E. R. (2025) · Antioxidants · doi:10.3390/antiox14020125 · Cited by 63
Dermentzaki, G., Dimitriou, E., Xilouri, M., Michelakakis, H., & Stefanis, L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060674 · Cited by 67
Metadata
- Authors
- Sidransky, E., Nalls, M. A., Aasly, J. O., Aharon-Peretz, J., Annesi, G., Barbosa, E. R., Bar-Shira, A., Berg, D., Bras, J., Brice, A., Chen, C.-M., Clark, L. N., Condroyer, C., De Marco, E. V., Dürr, A., Eblan, M. J., Fahn, S., Farrer, M. J., Fung, H.-C., Gan-Or, Z., Gasser, T., Gershoni-Baruch, R., Giladi, N., Griffith, A., Gurevich, T., Januario, C., Kropp, P., Lang, A. E., Lee-Chen, G.-J., Lesage, S., Marder, K., Mata, I. F., Mirelman, A., Mitsui, J., Mizuta, I., Nicoletti, G., Oliveira, C., Ottman, R., Orr-Urtreger, A., Pereira, L. V., Quattrone, A., Rogaeva, E., Rolfs, A., Rosenbaum, H., Rozenberg, R., Samii, A., Samaddar, T., Schulte, C., Sharma, M., Singleton, A., Spitz, M., Tan, E.-K., Tayebi, N., Toda, T., Troiano, A. R., Tsuji, S., Wittstock, M., Wolfsberg, T. G., Wu, Y.-R., Zabetian, C. P., Zhao, Y., & Ziegler, S. G.
- Affiliations
- National Institutes of Health (US)
- National Human Genome Research Institute (US)
- Corresponding author
- Sidransky, E.
- ORCID
- Sidransky, E.
- Nalls, M.A.
- Aasly, J.O.
- Annesi, G.
- Barbosa, E.R.
- Berg, D.
- Brice, A.
- Chen, C.-M.
- Clark, L.N.
- Condroyer, C.
- Dürr, A.
- Farrer, M.J.
- Fung, H.-C.
- Gasser, T.
- Giladi, N.
- Gurevich, T.
- Kropp, P.
- Lang, A.E.
- Lesage, S.
- Marder, K.
- Mata, I.F.
- Mirelman, A.
- Mitsui, J.
- Mizuta, I.
- Nicoletti, G.
- Oliveira, C.
- Ottman, R.
- Pereira, L.V.
- Quattrone, A.
- Rogaeva, E.
- Rosenbaum, H.
- Rozenberg, R.
- Schulte, C.
- Sharma, M.
- Singleton, A.
- Spitz, M.
- Tan, E.-K.
- Tayebi, N.
- Toda, T.
- Tsuji, S.
- Wittstock, M.
- Wolfsberg, T.G.
- Wu, Y.-R.
- Zabetian, C.P.
- Zhao, Y.
- Ziegler, S.G.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-10-22
- Volume
- 361
- Issue
- 17
- Pages
- 1651-1661
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC2856322
- OpenAlex
- W2170281382
- Cited by
- 2,135
- References
- 43
- Citations by year
- 2026: 128 · 2025: 147 · 2024: 156 · 2023: 156 · 2022: 149 · 2021: 155 · 2020: 174 · 2019: 136 · 2018: 135 · 2017: 115 · 2016: 118 · 2015: 118 · 2014: 95 · 2013: 103 · 2012: 84
- FWCI
- 54.96
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Scientific Electronic Library Online (São Paulo Research Foundation, Latin American and Caribbean Center on Health Sciences Information, Conselho Nacional de Desenvolvimento Científico e Tecnológico) (publishedVersion)
- PubMed Central (acceptedVersion)
- National University of Singapore (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- University of Washington
- National Institutes of Health (Z99 HG999999)
- National Institute on Aging (Z01AG000957)
- National Human Genome Research Institute (ZIAHG200336)
- National Institute of Neurological Disorders and Stroke (R56NS036630, R21NS050487, NS 40256, NS050487, R01NS036630, R01NS060113, NS060113)
- National Center for Research Resources (UL1RR024156)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Glycogen Storage Diseases and Myoclonus
- Keywords
- Parkinson's disease, glucocerebrosidase, GBA mutations, Ashkenazi Jews, Gaucher disease, mutation frequency, genotype-phenotype correlation, atypical presentation, familial Parkinson's disease
- MeSH terms
- Aged, Genotype, Glucosylceramidase, Humans, Jews, Middle Aged, Mutation, Parkinson Disease, Multivariate Analysis, Logistic Models, Odds Ratio, Case-Control Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.